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Characterisation of Diabetes Mellitus in Dogs 
Abstract 
Diabetes mellitus is considered a common endocrine disorder in dogs. The 
underlying pathology is, however, poorly understood. Epidemiological, genetic and 
clinical research, as well as the clinical management of diabetic dogs, requires an 
appropriate system of classification that provides a framework within which various 
forms and stages of diabetes mellitus can be identified and differentiated. The overall 
aim of this doctoral research was to further characterise the different subtypes of 
canine diabetes mellitus.  
In the first study, a population-based epidemiological study, breed- gender- and 
age-specific incidence rates were calculated, and survival after diagnosis was 
estimated. A major finding was that in some breeds such as elkhounds and border 
collies, only female dogs were affected by diabetes.  
In the second study, beta cell function was assessed in dogs through measurement 
of C-peptide before and after an intravenous injection of glucagon. Healthy dogs 
showed a marked increase in the serum concentration of C-peptide after glucagon 
stimulation, indicating that the test is suitable for the purpose. In most diabetic dogs, 
C-peptide did not increase after glucagon stimulation, indicating beta cell 
dysfunction. The test has a potential use for subtyping diabetes mellitus in newly 
diagnosed dogs.  
A specific subtype of diabetes, gestational diabetes mellitus, was clinically 
characterised in the third study. Gestational diabetes mellitus is rare in dogs, and the 
case series in this study is the largest one described to date.  
In the fourth study, diabetes mellitus was investigated in 63 Swedish and 
Norwegian elkhounds. From the latter two studies it was concluded that those 
elkhound breeds are predisposed to progesterone-related forms of diabetes mellitus 
(diœstrous and gestational diabetes mellitus), which have several characteristics in 
common with human gestational diabetes mellitus and may serve as a novel animal 
model for that disease.  
A new classification system for canine diabetes mellitus is proposed based on the 
basis of earlier studies and the newly gained knowledge. The following classes are 
proposed: juvenile; progesterone-related; secondary to pancreatic insult; endocrine 
tumours; iatrogenic; immune-mediated; and idiopathic. 
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“Do not seek to follow in the footsteps of the old men; seek what they sought”  
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1  Introduction 
Diabetes mellitus consists of a group of metabolic diseases that are 
characterised by a chronic excess of blood glucose, resulting from defects in 
insulin secretion, insulin action, or both (ADA, 2003). Diabetes mellitus 
constitutes a major global public health problem in humans, and is also of 
concern in dogs. Although diabetes mellitus is considered to be a common 
endocrine disorder in dogs, its underlying disease mechanisms are poorly 
understood. The overall aim of this doctoral research further characterise the 
different subtypes of canine diabetes mellitus. 
Common concepts in the field of diabetes mellitus are summarised in 
chapter  2. Sections 2.1-2.3  and 2.5 are based on studies in humans and 
laboratory animals, while section 2.4 cover dog-specific features. The 
following chapters (3-7) describe and discuss the four studies included in the 
doctoral work. Furthermore, a new classification system for canine diabetes 
mellitus is proposed based on earlier and newly gained knowledge. 
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2  Diabetes mellitus 
2.1  Physiology 
2.1.1  Glucose uptake and transport 
Glucose, blood sugar, represents a major source of energy for mammalian 
cells. Glucose is obtained directly from the diet, and by synthesis from 
substrates in organs such as the liver (Wood & Trayhurn, 2003). Brain cells 
and red blood cells are entirely dependent on glucose as their energy source. 
Glucose is stored in the liver and muscle as glycogen. Because cell 
membranes are impermeable to polar molecules, the transport of glucose 
into cells requires specific transport proteins. Two classes of glucose 
transport proteins have been described in mammalian cells: the sodium-
dependent glucose co-transporter and the facilitative glucose transporters 
(glut)(Mueckler, 1994).  
The sodium-dependent glucose co-transporter is expressed in the kidney 
and small intestine (Wright, 2001). Facilitative glucose carriers are expressed 
by most, if not all cells. They have different isoforms, which have distinct 
tissue distributions. The isoform glut-4 transports glucose into muscle and 
adipose tissue and is activated by the hormone insulin, which is secreted by 
the endocrine parts of the pancreas (Zhao & Keating, 2007).  
2.1.2  Insulin synthesis and secretion 
Insulin is rapidly secreted in response to elevations of blood glucose. Insulin 
is secreted endocrine cell clusters in the pancreas, which are named the islets 
of Langerhans after their discoverer. These cell clusters contain different types 
of cells, which produces hormones such as insulin, glucagon, somatostatin, 
ghrelin, and pancreatic polypeptide (Huang et al., 2009; Wierup et al., 2002). 
Insulin is produced and secreted solely by beta cells in the islets of 
Langerhans (Rutter, 2001).    12
Glucose sensing and insulin secretion  
Glucose is constantly transported across the beta cell membrane through 
glut-2/glut-1, which keeps extracellular and intracellular glucose 
concentrations similar (Richardson et al., 2007; Rutter, 2001). Glucose must 
be metabolised through glycolysis, to exert any significant effect on the beta 
cell. The intracellular enzyme glucokinase, which is responsible for the first 
step of glycolysis, has some specific characteristics which make it the rate-
limiting step of the beta cell ‘‘glucose sensor system’’ (Matschinsky et al., 
1986). Glucose metabolites are further processed within the beta cell 
mitochondria which results in an increased atp/adp ratio and ultimately 
membrane depolarisation by impeding potassium efflux. This depolarisation 
will lead to an influx of extracellular calcium, which will trigger the 
exocytosis of insulin (Ammala et al., 1993). (See Figure 1).  
The insulin secretory response is greater after oral than after intravenous 
administration of glucose, as an effect of gut hormones and other 
mechanisms that sensitise the beta cell to glucose metabolites (Cavaghan & 
Polonsky, 2005). 
Figure 1. Simplified schematic representation of signalling pathways in pancreatic beta cells. 
Drawn by the author.    13 
Biosynthesis 
The synthesis of insulin includes transcription of the preproinsulin gene 
(INS) to mrna, translation of mrna into preproinsulin, and processing of 
preproinsulin via proinsulin into mature insulin, which is stored in two 
pools of granulæ, one of them docked to the cell membrane and the other 
one waiting in the cytoplasm (Daniel et al., 1999). During the processing of 
proinsulin, a peptide called C-peptide is cleaved off to form insulin. Mature 
insulin is composed of two peptide chains, the A and B chains. The amino 
acid sequence of proinsulin differs among species. The amino acid sequence 
of proinsulin in the dog is shown in Figure 2, with indications of differences 
with the human sequence.  
The metabolites of glucose stimulate biosynthesis of insulin. About one 
hour after an increase in serum glucose, the production of insulin will reach 
a maximum, with a concentration as much as 10- to 20-fold higher than 
basal levels (Guest et al., 1989).  
 
 
Figure 2. Amino acid sequence of dog proinsulin. The amino acids marked in red differ 
between dogs and humans. Straight lines indicate cleavage points. Drawn by the author on 
the basis of information in (Kwok et al., 1983; Bell et al., 1979). 
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2.1.3  Insulin effect 
Insulin is an anabolic hormone with major systemic effects. It increases 
glucose uptake in muscle and fat, and inhibits hepatic glucose production, 
thus serving as the primary regulator of the blood glucose concentration. 
Insulin also stimulates cell growth and differentiation, and promotes the 
storage of substrates in fat, liver and muscle by stimulating lipogenesis, 
glycogen and protein synthesis, and inhibiting lipolysis, glycogenolysis and 
protein breakdown (Saltiel & Kahn, 2001). See Figure 3 for a schematic 
representation of the effect of insulin. 
 
 
 
 
 
Figure 3. Schematic representation of the metabolic effects of the activated insulin receptor in
muscle and fat cells. Drawn by the author from information in Saltiel & Kahn (2001). FFA;
free fatty acids.   15 
Insulin acts through the insulin receptor, which is a so called tyrosine kinase 
receptor (reviewed in Patti & Kahn, 1998). When insulin binds to the 
receptor, the receptor itself becomes phosphorylated and activates a number 
of signalling cascades within the cell. Vesicles containing glut-4 are 
transported from intracellular storage to the cell membrane, allowing 
glucose influx. These pathways also influence protein synthesis, enzyme 
activation and inactivation, and gene expression, resulting in the regulation 
of glucose, lipid and protein metabolism (Kahn & Saltiel, 2005). 
2.2  Summary of important disease mechanisms 
When an insufficient amount of insulin is secreted and/or the tissue 
sensitivity to insulin is low, diabetes mellitus will develop. The symptoms of 
diabetes mellitus are mainly attributable either to the abundance of glucose 
in the blood or to the shortage of nutrients within cells. The classical 
symptoms of diabetes mellitus include increased thirst, increased production 
of urine, increased appetite and weight loss. The name of the syndrome 
relates to the glycosuria seen in diabetic patients."Diabetes" is derived from a 
Greek word meaning 'siphon' or ‘flow’. "Mellitus" is a Latin adjective 
meaning 'honey-like'. Diabetes mellitus is often referred to simply as 
"diabetes", and in this thesis, both expressions will be used. 
At the beginning of the last century, insulin deficiency due to beta cell 
destruction was considered to be the main cause leading to diabetes mellitus 
in humans. Mechanisms such as autoimmune events and chemical stress due 
to toxins or pancreatitis may cause destruction of islets. The ability of beta 
cells to proliferate is limited, especially in adults. Some degree of 
regeneration can occur after physiological stimulation such as pregnancy 
(Butler et al., 2007) or injury (Dor et al., 2004) but the “new” beta cells are 
thought to derive from already existing insulin-expressing cells in the 
pancreatic duct epithelium. Other causes of defective insulin secretion may 
include malfunctioning glucose metabolism in the beta cell, due, for 
example, to defects in beta cell glucokinase, as is the case in a rare form of 
diabetes with dominant inheritance, namely mature onset diabetes mellitus 
of the young type 2 (mody2) (Froguel et al., 1993).  
After the development of a radioimmunoassay for measuring insulin by 
Yalow and Berson (1960), it became obvious that the majority of human 
diabetic patients had residual insulin secretion at diagnosis. Their diabetes 
mellitus seemed to be attributable to reduced peripheral tissue sensitivity to 
insulin.
1 Many factors are now known to reduce the tissue sensitivity to 
                                                  
1 Mainly patients with type 2 diabetes mellitus   16
insulin, including visceral adiposity, inflammation, infections, 
glucocorticoids, pregnancy, and genetic defects in the insulin receptor 
(Reaven,  1998). In a person with insulin resistance (decreased insulin 
sensitivity), beta cells will normally meet the augmented demands by 
increasing their production of insulin. If the beta cells cannot meet these 
high demands, hyperglycaemia will develop. This phenomenon is called 
relative insulin deficiency. 
Chronic hyperglycaemia may in itself cause irreversible damage to beta 
cells. This phenomenon is termed glucotoxicity. Imamura et al (1988) showed 
that chronic clamping of plasma glucose levels at greater than or equal to 14 
mmol/l in four partially depancreatised healthy dogs led to an insulin-
dependent diabetes mellitus. Histological examination of the endocrine 
pancreas revealed a profound reduction of the number and size of 
identifiable islets in the hyperglycaemic dogs when compared with biopsy 
samples from the same pancreata obtained months earlier and with those 
from eight partially depancreatised control dogs that had not been subjected 
to chronic hyperglycaemic clamping. The underlying concept of 
glucotoxicity is that once the primary
 pathogenesis of diabetes is established, 
hyperglycaemia and commonly hyperlipidaemia ensue, with
  damaging or 
toxic effects on the beta cell (Poitout & Robertson, 2008), but the exact 
mechanisms remain elusive. One part of the explanation is proposed to be 
increased apoptosis caused by endoplasmic reticulum stress. The beta cell 
endoplasmic reticulum, which folds new proteins, may be overloaded and 
send apoptosis signals when the demand for insulin is too high (Laybutt et 
al., 2007).  
2.3  Diagnostic tests for estimation of insulin secretion and 
action 
2.3.1  Insulin secretion 
There are various approaches to assessment of beta cell function in clinical 
settings. In most instances, an estimate of stimulated secretion of insulin and 
C-peptide will provide more information than basal secretion (Madsbad et 
al.,  1981). Beta cells may be stimulated by orally or intravenously 
administered compounds e.g. glucose, glucagon or arginine. C-peptide is 
often measured as a marker of insulin secretion. C-peptide has negligible 
hepatic extraction compared to insulin and a much longer half-life 
(Polonsky et al., 1984). Moreover, exogenous insulin in treated patients does 
not interfere with the C-peptide analysis, as it would with an insulin assay. 
The concentration of C-peptide six minutes after an intravenous bolus of   17 
glucagon is often used to assess residual beta cell function in patients with 
diabetes (Scheen et al., 1996; Faber & Binder, 1977).  
2.3.2  Insulin sensitivity 
Numerous different techniques for estimating the effect of insulin in 
peripheral tissue have been reviewed by Monzillo and Hamdy (2003). One 
of the two gold standard methods approved by the American Diabetes 
Association (1998) is the hyperinsulinaemic euglycaemic clamp, in which 
the patient is exposed to a predetermined amount of insulin while the 
plasma glucose is maintained within the euglycaemic range by infusion of 
glucose. The amounts of insulin and glucose administered are used to 
calculate the insulin sensitivity. The other gold standard method is the 
“frequently sampled intravenous glucose tolerance test”, where glucose is 
administered and samples for glucose and insulin are analysed at numerous 
time points. The test results from this method are more variable than those 
from the hyperinsulinaemic euglycaemic clamp (Steil et al.,  1994). Both 
methods, however, are labour-intensive. 
2.4  Canine diabetes mellitus 
2.4.1  Historical perspective 
Spontaneous diabetes mellitus in dogs was described as early as in 1861 in 
two case reports (Leblanc, 1861; Thiernesse, 1861). One of the cases was 
reported in a 15-year old petit griffon, and in the other one in a 6-year old 
sighthound. At that time, diabetes mellitus was diagnosed by the presence of 
glycosuria, but the analysis was not readily available. In the sighthound case, 
the diagnostic suspicion was first investigated by the attending veterinarian, 
by tasting the urine and finding it sweet (Leblanc, 1861). Fröhner (1892) 
reported on the first case series of five diabetic dogs and estimated the 
frequency of diabetes mellitus to be 1:10,000 dogs in his veterinary practice.  
Dogs were used extensively as experimental animals during the “insulin 
discovery era” and were crucial both for the discovery of “pancreatic 
diabetes mellitus” in 1893 by Minkowski and Mering and in the discovery 
and isolation of insulin in 1921 by Banting and Best (Minkowski, 1929 
reprinted in 1989). 
Reports on larger case series of spontaneous diabetes in dogs did not 
appear until the 1960s and originated from the United Kingdom and 
Sweden (Krook et al., 1960; Wilkinson, 1960). Ricketts et al (1953) found 
that diabetes mellitus occurs mainly in older dogs. He also found that the 
ratio of affected female to male dogs was 3 to 1. This finding was confirmed   18
in a number of studies, but with somewhat different ratios (Foster, 1975). 
Campbell (1958) and Wilkinson (1960) reported that many of the female 
cases developed shortly after œstrus. Wilkinson also wrote that 
ovariohysterectomy may seem a drastic therapeutic measure for diabetic 
female dogs, but that he would nevertheless recommend it. 
Few authors committed themselves to the issue of breed predominance 
in diabetes prior to the doctoral research of Wilkinson (1960). He identified 
five breeds besides mongrels that he considered to have a higher incidence 
than the general population, namely the dachshund, spaniel, poodle, fox 
terrier and cairn terrier. Krook (1960), reported that the rottweiler, 
dachshund, spaniel, Swedish hound (now called Hamilton hound) and 
mongrel were overrepresented in his Swedish pathology material. 
A milestone in canine diabetology was the discovery of progesterone-
induced mammary growth hormone (gh) and its relationship to diabetes 
mellitus (Selman et al.,  1994b; Eigenmann et al.,  1983). During the last 
decade, the interest for the ætiology of canine diabetes mellitus has increased 
with a number of interesting studies being published, mainly focusing on 
autoantibodies, dla association, and candidate genes (Davison et al., 2008; 
Short et al., 2007; Kennedy et al., 2006). 
2.4.2  Clinical manifestations 
Dogs with diabetes mellitus show all the classical symptoms seen in humans. 
The major complaint at first consultation is usually an increased thirst and 
increased urination. The owner might also have noticed weight loss, in spite 
of a good appetite. Other symptoms may be a dull hair-coat, muscle 
wasting, tiredness, loss of vision, and infections (Foster, 1975). If the dog is 
not correctly treated for its disease, it may pass into a ketoacidotic state, 
which is a severe condition that requires intensive care.  
Most dogs are older than five years at onset of diabetes mellitus (Davison 
et al., 2005; Guptill et al., 2003). Several studies have shown that female dogs 
have an increased risk for diabetes (Guptill et al., 2003; Marmor et al., 1982; 
Foster, 1975; Krook et al., 1960), but in one recent large British study this 
association was not confirmed (Davison et al., 2005). 
2.4.3  Diagnosis 
The diagnosis is based on measurement of glucose in the blood and urine. 
Healthy dogs do not have detectable amounts of glucose in the urine and 
have fasting blood glucose concentration between 3.5 and 6.0 mmol/L.
2 In 
                                                  
2Reference range, Clinical Pathology Laboratory, University Animal Hospital at the Swedish 
University of Agricultural Sciences   19 
general veterinary practice, tests for insulin secretion are not performed. 
Dogs are sometimes tested for concurrent and potentially diabetogenic 
disorders, such as hyperadrenocorticism or pancreatitis. 
2.4.4  Treatment 
Dogs with diabetes mellitus are most often dependent on insulin for survival 
(Ling et al., 1977). Dog owners are instructed how to give subcutaneous 
injections of insulin and how to treat a potential hypoglycaemia. One year 
survival is reported to be 64% among dogs that survive stabilisation with 
insulin (Doxey et al., 1985). Intact female dogs are usually spayed shortly 
after diagnosis, because of the insulin-antagonistic features of the sex 
hormone progesterone (Eigenmann et al., 1983). 
2.4.5  Occurrence 
Diabetes mellitus is considered to be a common endocrinopathy in dogs. 
The incidence is unknown, since all published epidemiological studies have 
been cross-sectional or hospital-based. The reported prevalence has varied 
from 0.3 % to 1.3 % (Davison et al., 2005; Fracassi et al., 2004; Guptill et al., 
2003). Some studies have shown a winter peak in the onset of canine 
diabetes (Davison et al., 2005; Atkins & MacDonald, 1987) whereas in other 
studies no seasonal predisposition has been found (Guptill et al.,  2003; 
Marmor et al., 1982).  
Certain breeds have been shown to have either an increased or a 
decreased risk of developing the diabetes mellitus, implying the existence of 
important genetic factors in the aetiology. Breeds that are consistently 
reported to have a high frequency of diabetes are the samoyed, cairn terrier 
and Australian terrier, and those that are consistently reported to have a low 
frequency are the golden retriever, boxer and the German shepherd 
(Davison et al., 2005; Fracassi et al., 2004; Guptill et al., 2003; Hess et al., 
2000a; Doxey et al., 1985; Marmor et al., 1982; Krook et al., 1960). 
2.4.6  Assessment of beta cell function 
Previous studies of insulin secretion in diabetic dogs have yielded 
contradictory results, probably because of the different populations tested 
and the different diagnostic criteria for diabetes mellitus applied. 
Mattheuuws et al (1984) studied 71 diabetic dogs and found that 32 of them 
had no insulin secretion, 15 had high basal insulin but no response to an 
intravenous glucose load and 24 showed a significant increase in insulin after 
an intravenous glucose load. The inclusion criterion for the dogs in that 
study was a blood glucose concentration of >6.7 mmol/L. Many of the dogs   20
in the study were asymptomatic. Montgomery et al (1996) used an inclusion 
criterion of a fasting blood glucose >13.9 mmol/L combined with clinical 
signs of diabetes mellitus and reported that 35/42 diabetic dogs had low or 
absent C-peptide concentrations even after intravenous glucagon 
stimulation, indicating an absolute insulin deficiency. However, 7 of the 42 
dogs had a basal insulin secretion higher than in healthy dogs, but with a 
lower increment after stimulation, which could correspond to insulin 
resistance and beta cell exhaustion. Eigenmann et al (1983) tested 21 dogs 
with either acromegaly or diabetes mellitus secondary to progestin (synthetic 
progesterone) treatment or diœstrus. Only ten of these animals had glucose 
concentrations of >10 mmol/L. All dogs in that study showed a marked 
hyperinsulinemia that responded little or not at all to an intravenous glucose 
load.  
2.4.7  Histopathology 
Findings in pancreatic biopsy samples from diabetic dogs have been 
conflicting. Two fairly large studies of diabetic dogs (Ling et al., 1977; Gepts 
& Toussaint, 1967) (n=33, n=30) have shown a reduced number or total 
absence of islets, together with degeneration, hyalinisation or vacuolisation. 
Pancreatic biopsy samples from dogs with diabetes mellitus secondary to 
progestin treatment or diœstrus also showed degeneration and vacuolisation 
of the beta cells (Eigenmann et al., 1983). Insulitis was not seen in any of 
these three studies. 
On the other hand, Alejandro et al (1988) reported that 6/13 diabetic 
dogs in their study had lymphocytic infiltration associated with islets 
(insulitis) and that 5/18 displayed extensive exocrine pancreatic damage. 
There were no control group in any of these studies. The latter report is 
often referred to by textbooks and review articles, indicating that a third of 
diabetes mellitus cases are attributable to pancreatitis (Catchpole et al., 2005; 
Rand et al., 2004). However, a recent study showed that chronic pancreatitis 
is a common finding at autopsies of dogs in general practice. In that 
particular study 34% of 200 dogs with various diseases were considered as 
having chronic pancreatitis (Watson et al., 2007).  
Histopathological investigation in 12 juvenile diabetic Greyhounds 
revealed extensive exocrine and endocrine atrophy of the pancreas (Brenner 
et al., 2009). 
2.4.8  Immune markers 
Autoantibodies directed against glutamic acid decarboxylase 65 (gad65) and 
ia-2, a tyrosine phosphatase-like protein, is common in immune-mediated   21 
human diabetes (type 1 diabetes). Alejandro et al (1988) did not find any 
evidence of autoreactive components in the sera of 18 diabetic dogs. Hoenig 
and Dawe (1992) observed an unspecific anti-islet reactivity in sera from 
nine out of 23 newly diagnosed dogs with diabetes representing various 
breeds. One recent study showed that five out of 30 investigated diabetic 
dogs had gad65 and ia-2  antibodies. It is unclear whether these 
autoantibodies indicate a autoimmunity process, or are secondary to an 
immune response against antigens that are released as a consequence of beta 
cell destruction by some other disease process (Davison et al., 2008). 
2.4.9  Genetic markers 
The canine equivalent of the human leucocyte antigen (hla) system is the 
dog leucocyte antigen (dla). The most polymorphic loci are drb1, dqa1 
and dqb1. Currently 100 drb1, 26 dqa1 and 60 dqb1 alleles have been 
officially recognised to date, with extensive interbreed but minimal 
intrabreed dla variation (Kennedy et al., 2007). Three dla haplotypes,
3 has 
been shown to be associated with diabetes in dogs, with odds ratios of 1.5-2 
(Kennedy et al., 2006).  
A large cohort of British dogs were genotyped for single nucleotide 
polymorphisms in a number of type 1 diabetes susceptibility genes, including 
cytokines, insulin and immunoregulators, Several associations were found in 
the study with the most strong association for an interleukin-10 haplotype in 
Cavalier King Charles spaniels (Short et al., 2007). 
2.4.10  Relation to other endocrine diseases  
Insulin resistant diabetes may occur in the presence of hormonal 
disturbances,  e.g. hyperadrenocorticism and progesterone-induced 
acromegaly (Peterson et al., 1984; Eigenmann et al., 1983). The luteal phase 
of the œstrous cycle in the non-pregnant dog mimics the pregnancy with 
respect to its length and hormone concentrations. In some dogs, diabetes 
develops during the luteal phase, when it is referred to as diœstrous diabetes 
(Foster, 1975). In the study by Eigenmann et al (1983), diœstrous diabetic 
cases had significantly higher serum concentrations of gh than controls, 
during a glucose tolerance test. It was later found, that female dogs expressed 
gh, which reached systemic levels, in the mammary gland under exposure of 
progestins (Selman et al., 1994b). The excess of gh may contribute to the 
development of diabetes mellitus in susceptible dogs. Insulin-like growth 
factor-1 ( igf-1) is expressed in the liver under influence of gh and has 
                                                  
3 drb1*009/dqa1*001/dqb1*008, drb1*015/dqa1*0061/dqb1*023 
and drb1*002/dqa1*009/dqb1*001   22
shown to be increased in female dogs treated with progestins (Bhatti et al., 
2007; Selman et al., 1994a). In dogs with diabetes due to insulin resistance, 
diabetes may or may not be transient after treatment of the cause of insulin 
resistance. Untreated insulin resistant diabetes can lead to insulin deficiency 
as a consequence of chronic hyperglycaemia, which in itself can produce 
permanent beta cell dysfunction, probably due to glucotoxicity (Imamura et 
al.,  1988). Diœstrous diabetes is generally considered common in 
populations, where spaying of young female dogs is rare, but there no 
further investigations have been published on this subject since 1983. 
In a study by Hess et al (2000b), who investigated concurrent disorders in 
221 dogs with diabetes mellitus, 23% were found to have concurrent 
hyperadrenocorticism (Cushing’s syndrome). Peterson and co-workers 
performed glucose and insulin tolerance tests in 60 dogs with untreated 
hyperadrenocorticism. Most dogs showed hyperinsulinaemia, except for a 
few dogs with overt diabetes mellitus and hypoinsulinaemia (Peterson et al., 
1984).  
2.5  Human diabetes mellitus 
The aetiology and epidemiological features of diabetes in humans are 
heterogeneous. The terminology and classification of human diabetes 
mellitus have changed over the years towards an aetiology-based system. 
The World Health Organisation (who) and an expert committee from the 
American Diabetes Association (ada) have recently each published a 
document with essentially the same classification system of diabetes mellitus 
(Table 1) (ADA, 2003; WHO, 1999). The capacity for insulin secretion and 
the magnitude of insulin resistance vary with the type of diabetes mellitus 
and also within the type, depending on the stage of the disease.  
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Table 1. Aetiological classification of diabetes mellitus in humans  
I. Type 1 diabetes mellitus (beta-cell destruction, usually leading to absolute insulin 
deficiency4) 
A. Immune mediated 
B. Idiopathic 
 
II. Type 2 diabetes mellitus (may range from predominantly insulin resistance with relative 
insulin deficiency to a predominantly secretory defect with insulin resistance) 
 
III. Other specific types 
A. Genetic defects of beta cell function 
1. Chromosome 12, HNF-1-alpha (mody3) 
2. Chromosome 7, glucokinase (mody2) 
3. Chromosome 20, HNF-4-alpha (mody1) 
4. Mitochondrial DNA 
5. Others 
B. Genetic defects in insulin action 
1. Type A insulin resistance 
2. Leprechaunism 
3. Rabson-Mendenhall syndrome 
4. Lipoatrophic diabetes mellitus 
5. Others 
C. Diseases of the exocrine pancreas 
1. Pancreatitis 
2. Trauma/pancreatectomy 
3. Neoplasia 
4. Cystic fibrosis 
5. Haemochromatosis 
6. Fibrocalculous pancreatopathy 
7. Others 
D. Endocrinopathies 
1. Acromegaly 
2. Cushing’s syndrome 
3. Glucagonoma 
4. Phaeochromocytoma 
5. Hyperthyroidism 
6. Somatostatinoma 
7. Aldosteronoma 
8. Others 
                                                  
4 Patients with any form of diabetes mellitus may require insulin treatment at some stage of their 
disease. Such use of insulin does not, in itself, classify the patient.   24
E. Drug- or chemical-induced 
1. Vacor 
2. Pentamidine 
3. Nicotinic acid 
4. Glucocorticoids 
5. Thyroid hormone 
6. Diazoxide 
7. Beta-adrenergic agonists 
8. Thiazides 
9. Dilantin 
10. alpha-Interferon 
11. Others 
F. Infections 
1. Congenital rubella 
2. Cytomegalovirus 
3. Others 
G. Uncommon forms of immune-mediated diabetes mellitus 
1. “Stiff-man” syndrome 
2. Anti-insulin receptor antibodies 
3. Others 
H. Other genetic syndromes sometimes associated with diabetes mellitus 
1. Down syndrome 
2. Klinefelter’s syndrome 
3. Turner’s syndrome 
4. Wolfram’s syndrome 
5. Friedreich’s ataxia 
6. Huntington’s chorea 
7. Laurence-Moon-Biedl syndrome 
8. Myotonic dystrophy 
9. Porphyria 
10. Prader-Willi syndrome 
11. Others 
IV. Gestational diabetes mellitus 
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2.5.1  Type 1 diabetes mellitus 
This form of diabetes was previously encompassed by the terms insulin-
dependent diabetes mellitus (iddm) or juvenile-onset diabetes mellitus. It is 
most often observed in children, but may also occur in adults (World Health 
Organisation, 1999). Destruction of beta cells is the crucial event leading to 
type  1 diabetes with ensuing cessation of insulin secretion (Bennet & 
Knowler, 2005). Individuals with type 1 diabetes are dependent on insulin 
for survival and are prone to develop ketosis if not treated properly. 
The presence of certain autoantibodies against islet cells (ica) is 
commonly reported in type 1 diabetes. These autoantibodies are mainly 
directed against glutamic acid decarboxylase 65 (gad65) and ia-2, a tyrosine 
phosphatase-like protein. Individuals possessing one or more of these 
autoantibodies can be subclassified as having autoimmune type 1 or type 1a 
diabetes mellitus (World Health Organisation, 1999). These autoantibodies 
may be detected years before the onset of clinical disease (Knip et al., 1998). 
This subtype, type 1a,  shows a strong genetic association with the human 
leucocyte antigen (hla). The HLA-DR/DQ alleles with association with 
type 1 diabetes can be either predisposing or protective (Nejentsev et al., 
2007). 
There are, especially in the non-white population, patients with insulin 
deficiency at diagnosis and ketoacidosis without the presence of 
autoimmunity. These patients are classified as having idiopathic type 1 or 
sometimes type 1b (World Health Organisation, 1999). There is an ongoing 
discussion on reclassification of this group as ketosis-prone diabetes instead 
of type 1 diabetes, as these patients may have a transient need for insulin 
treatment (Balasubramanyam et al., 2008).  
In Sweden, the incidence of type 1 diabetes is 3.4 cases per 10,000 years at 
risk in children younger than 15 years (Patterson et al., 2009). The incidence 
of type 1 diabetes is increasing by about 4% per year in Europe and it is 
estimated that the incidence will be nearly doubled by the year 2020 
compared to year 2005 (Patterson et al., 2009). Studies have shown different 
risk estimates for type 1 diabetes in different countries, in different seasons of 
the year, and in rural compared to urban areas (Karvonen et al.,  2000; 
Patterson et al., 1996; Levy-Marchal et al., 1995).  
A variant of autoimmune diabetes mellitus is the latent autoimmune 
diabetes in adults (lada). This form of diabetes differs from type 1 diabetes 
in clinical characteristics by showing a more preserved beta cell function at 
diagnosis (Stenstrom et al., 2005). Although patients diagnosed with lada do 
not by definition require insulin early after diagnosis, within six years, the   26
beta cell function is severely impaired, leading to dependency on insulin 
medication (Littorin et al., 1999).  
2.5.2  Type 2 diabetes mellitus 
Type 2 diabetes was previously covered by the terms non-insulin-dependent 
diabetes mellitus (niddm) and adult-onset diabetes mellitus (World Health 
Organisation, 1999).  
Type  2  diabetes is often associated with obesity and develops when 
chronic overnutrition occurs concomitantly with genetic susceptibility to 
insulin resistance as well as in the presence of a relative insulin deficiency of 
non-autoimmune aetiology. Insulin resistance develops as a consequence of 
inflammatory and hormonal factors, endoplasmic reticulum stress, and 
accumulation of by-products of nutritional ‘overload’ in insulin-sensing 
tissues. Overnutrition is thought to increase the burden of the adipocyte 
endoplasmic reticulum, which may lead to a disruption of the normal 
folding of proteins and an activation of the unfolded protein response, 
which is known to induce stress response pathways (Ozcan et al., 2004). 
Beta cell failure triggers the transition from an obese, insulin-resistant 
state to full blown type 2 diabetes. The beta cell failure involves both a 
partial loss of beta cell mass and a deterioration of cell function. (Muoio & 
Newgard,  2008). In type 2 diabetes patients, residual insulin secretion is 
common during an extended time after diagnosis. The incidence of type 2 
diabetes is estimated at 38 cases per 10,000 years at risk in people older than 
30 years in the county of Uppsala, Sweden (Ringborg et al., 2008). Several 
gene variations (alleles) associated with an increased risk of type 2 diabetes 
are described, most of them common in the  populations studied and 
conferring disorders of beta cell development and function (McCarthy & 
Zeggini, 2009). 
2.5.3  Other specific types of diabetes mellitus 
This group contains variants of diabetes that develop in association with 
disorders other than those defined as type 1, type 2 or gestational diabetes. 
The group comprises a variety of types of diabetes, in which the underlying 
disease or disease process can be identified in a relatively specific manner 
(e.g., diabetes secondary to pancreatic disease, endocrine disease, or 
administration of certain drugs). The extent of residual insulin secretion 
varies widely with the cause of the diabetes (World Health Organisation, 
1999).   27 
Monogenic defects of beta cell function 
Several forms of diabetes are associated with monogenic defects in beta cell 
function, characterised by onset of mild hyperglycaemia before the age of 25 
years. These are usually inherited in an autosomal dominant pattern and are 
usually referred to as maturity-onset diabetes mellitus of the young (mody). 
To date, the underlying point-mutations of nine different mody types have 
been identified (Nyunt et al., 2009). 
Diseases of the exocrine pancreas 
Any process that diffusely injures the pancreas can cause diabetes mellitus. 
Acquired processes include pancreatitis, pancreatic carcinoma and the effects 
of pancreatectomy (World Health Organisation, 1999). Over time, many 
patients with chronic relapsing pancreatitis develop diabetes mellitus. In one 
study the cumulative proportion of diabetes mellitus was 83% twenty-five 
years after the clinical onset of chronic pancreatitis (Malka et al., 2000). 
Acromegaly 
Growth hormone is secreted from the anterior pituitary gland and the 
placenta. Hypersecretion of gh, leading to acromegaly, induces peripheral 
insulin resistance. Acromegaly in man is most often caused by a pituitary 
tumour. The precise nature of the diabetogenic effects of gh is not known, 
but they are probably related to both insulin receptor and postreceptor 
defects. Overt diabetes mellitus requiring insulin treatment was noted in 
30% of acromegalic patients in one study (Ezzat et al., 1994). The placental 
gh progressively replaces pituitary gh during pregnancy (Frankenne et al., 
1987). The increase of placental gh has been suggested to play a role in the 
development of gestational diabetes (see section 2.5.4). 
Hypercortisolism/Cushing’s syndrome 
Glucocorticoids are secreted by the adrenal cortex in response to an increase 
in secretion of adrenocorticotropic hormone. Cortisol, which is considered 
the most important glucocorticoid, has a profound effect on glucose 
homeostasis. Cortisol increases the hepatic glucose output and also seems to 
induce an insulin resistance. In patients with hypercortisolism, 80% are 
reported to have diabetes mellitus or glucose intolerance (Boscaro et al., 
2001).   28
Other types 
Other types of diabetes mellitus, including drug- or chemical-induced 
diabetes, specific infections, and rare genetic defects of insulin action, are 
not further described in this thesis. 
2.5.4  Gestational diabetes mellitus 
Gestational diabetes is defined as a carbohydrate intolerance that results in 
hyperglycaemia of varying degrees of severity with onset or first recognition 
during pregnancy. Individuals at high risk for gestational diabetes include 
older women and those with a history of glucose intolerance. About 2-12% 
of all human pregnancies (depending on the population and diagnostic 
criteria) are associated with gestational diabetes and even though the disease 
usually resolves after parturition, the risk for type 2 diabetes is increased later 
in life. The relative risk for type 2 diabetes after a diabetic pregnancy is 
about seven times higher than after a non-diabetic pregnancy (Bellamy et al., 
2009). Although human gestational diabetes is usually asymptomatic at 
diagnosis, the consequences may be substantial, with complications such as 
macrosomia, dystocia and neonatal hypoglycaemia (Hunt & Schuller, 2007; 
Brown & Goldfine, 2005).  
The insulin resistance normally observed during pregnancy plays an 
important role for the growth of the fœtus (Catalano et al., 1998). Several 
hormones such as progesterone, cortisol, and placental gh have been 
proposed as responsible for the insulin resistance seen in human pregnancies, 
but their individual roles and possible interactions are unclear (Kirwan et al., 
2002; Ryan & Enns, 1988). This insulin resistance plays an important part in 
the development of gestational diabetes. 
2.6  The dog as a genetic model for complex diseases 
The domestic dog has emerged as an ideal model for gene mapping of 
human complex diseases, as it has a spectrum of diseases similar to that in 
man, and also an advantageous population structure (Karlsson & Lindblad-
Toh, 2008). When dog breeds were created less than 200 years ago, the 
genetic variation within each breed became limited. The process had 
unintended consequences for the health of pure-bred dogs, with high rates 
of specific diseases in certain breeds, reflecting enrichment of risk alleles 
owing to random fixation at genetic bottlenecks and hitch-hiking of 
mutations near desirable traits.  
Dogs often share their environment with their owner, which is not the 
case for the most common model organism, the mouse. If something in the   29 
environment triggers disease in humans, it is possible that it will also affect 
the dog. In order to use dogs for finding gene variations associated with 
diabetes mellitus, it is important to clearly define different types of the 
syndrome in the dog. Thus, the research presented here should provide 
essential clinical information allowing successful identification of genetic risk 
factors for different subtypes of canine diabetes. 
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3  Aims 
The overall aim of this research was to further characterise different subtypes 
of canine diabetes mellitus.  
 
The specific aims were: 
 
to describe relevant epidemiological features of diabetes mellitus in 
the Swedish dog population with respect to breed, age and gender 
distribution; 
 
to evaluate the glucagon stimulation test for the assessment of beta cell 
function in diabetic dogs and potential differentiation of diabetes 
mellitus subtypes in dogs; 
 
to investigate whether subtypes of diabetes mellitus differs between 
breeds; 
 
to describe one specific subtype of canine diabetes mellitus 
concerning its clinical characteristics and prognosis. 
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4  Material and methods 
Overall issues regarding the dogs and research methods used in studies 
(papers) I-IV are outlined in this section. For detailed descriptions, the 
reader is referred to each individual paper.  
4.1  The Agria Insurance database 
The Swedish dog population is unique in that a large proportion of the 
animals are covered by an insurance plan and that most dogs are not 
neutered. The Agria insurance company
5 has been shown to cover 
approximately 30-40 % of the entire Swedish dog population (Egenvall et 
al.,  1999). The insured dog population in Sweden reflects the general 
Swedish dog population, with regard to gender distribution and breed 
structure. However, the mean age of the insured population (5.2 years) is 
somewhat lower than the general Swedish population (5.7 years) but the 
median ages are equal (5 years). This is explained by the different age limits 
that have been applied for the different insurance forms. In general, during 
the study period of paper I, life insurance ended at 10 years of age and the 
veterinary care insurance at 12 years of age. Mixed breeds and some breeds 
such as elkhounds and border collies are underrepresented in the insured 
population, with about 50 % of dogs insured for veterinary care compared 
to about 68 % in the general population (Egenvall et al., 1999). One of the 
advantages of using an insurance database like Agria for research is that it is 
possible to use for longitudinal cohort studies, starting with a large number 
of healthy dogs.  
                                                  
5 Agria Insurance, PO 70306, SE-107 23, Stockholm, Sweden   34
4.2  The Swedish Kennel Club 
The Swedish Kennel Club has kept fully computerised records of pedigrees 
and ownership of all pure-bred dogs in Sweden since the year 1976. In study 
IV, their register was accessed in order to find Swedish elkhounds of a 
susceptible age for diabetes mellitus. These dogs served as healthy control 
dogs. The Swedish Kennel Club registry was also accessed for pedigree 
information used for the study presented in study IV.  
4.3  The Swedish canine diabetes mellitus project 
A large number of participating diabetic and healthy dogs were required for 
the work of this doctoral research. The Swedish canine diabetes mellitus 
project (scdmp) was started as a basis for this work in December 2005. A 
broad network of veterinarians, veterinary nurses, breed clubs and dog 
owners was established. The network was recruited through articles, 
television interviews, lectures and newsletters. A special web-site 
(www.hunddiabetes.se) was created and letters directed to owners and 
veterinarians were sent out on a regular basis. Three major dog insurance 
companies (Agria Djurförsäkringar, Svealand and Folksam) made it possible, 
for the project, to contact owners of affected dogs.  
The samples and clinical information were collected mainly from Sweden 
and in a few instances from Norway. All treatments and sampling of dogs 
were approved by the owners and conformed with the decision of the 
Uppsala Animal Ethical Committee (no. C267/5) and the Swedish Animal 
Welfare Agency (no. 2005-2038).  
In study II, five veterinarians with a special interest in diabetes from 
different parts of the country were invited to participate in the study.  
Study III required medical records for dogs with gestational diabetes, and 
clinicians from 250 clinics were asked to share such records with the scdmp. 
The medical records for all diabetic dogs at three large animal hospitals were 
also reviewed with the aim of finding all dogs with onset of diabetes at 
pregnancy.  
Study IV was based on the medical records from 63 diabetic and 26 
healthy Swedish and Norwegian elkhounds.  
In total, 250 serum and EDTA samples from dogs affected by diabetes 
mellitus and 300 such samples from healthy dogs were collected within the 
project. The diagnosis of diabetes in each dog was based on clinical signs, 
including polyuria and polydipsia and fasting hyperglycaemia (>7 mmol/L). 
Blood samples were collected from each dog and were stored in -80°C until 
analysed. A questionnaire was completed by the owner of every dog that   35 
participated in the project and the veterinarian in charge supplied the 
medical records. The survey included questions on the date of onset of 
symptoms, concurrent disease, insulin regimen, castration date and feeding 
regimen. 
To evaluate the potential side effects of glucagon, an adverse effect 
protocol was attached to the questionnaires to the dog owner and attending 
veterinarian. The reported side effects are described in paper II.  
4.4  Clinical pathology 
All analyses were performed at the University Animal Hospital Laboratory, 
Swedish University of Agricultural Sciences. The analyses performed 
included:  
 
  Glucose (papers II and IV) 
  Fructosamine (paper II) 
  Insulin (paper II) 
  C-peptide (papers II and IV) 
  Progesterone (paper IV) 
 
The methods are described in detail in each paper. 
4.5  Methodological considerations concerning study II 
4.5.1  Dose of glucagon 
As mentioned above, the glucagon stimulation test was evaluated for use in 
dogs in study II. In the study by Montgomery et al (1996), it was shown that 
an intravenous bolus dose of 1 mg glucagon was sufficient to obtain a 
significant insulin release in dogs. Contact with other researchers using the 
test revealed, however, that in some dogs of miniature breeds this dose had 
adverse gastrointestinal effects. In a study of patients with type 2 diabetes and 
healthy controls, the C-peptide response to bolus doses of 0.5 mg and 1 mg 
glucagon were equivalent (Ahren et al., 1987). It was decided to give dogs 
<10 kg bodyweight a bolus dose of 0.5 mg and larger dogs a bolus dose of 1 
mg. To determine whether the different doses gave different C-peptide 
responses, the Wilcoxon rank sum test was performed to assess the 
difference between the six control dogs <10 kg and the 14 control dogs >10 
kg. The results and individual C-peptide concentrations are shown in Figure 
4. Since the population was small, the power for detecting differences was, 
however, low. The proportions of small dogs in the diabetes and control   36
dogs were similar in study II (9/31 and 6/20 d o g s  r e s p e c t i v e l y ) ,  w h i c h  
would reduce the risk of selection bias.  
In humans, C-peptide concentrations peaks 6 minutes after intravenous 
glucagon administration, but as the 10-minute  C-peptide had been found 
to be higher than the 5-minute sample in dogs in the study by Montgomery 
et al (1996), it was decided to not sample dogs after 5 minutes. 
 
 
 
Figure 4. C-peptide concentrations in a group of six healthy dogs weighing <10 kg receiving 
0.5 mg glucagon and in 14 healthy dogs >10 kg receiving 1 mg of glucagon. Samples are 
taken before and 10 and 20 minutes after intravenous administration of glucagon.  
4.5.2  Sample management 
Glucagon stimulation tests for the study II were performed at five centres in 
Sweden from January to October 2006, generating three serum tubes from 
each dog. After centrifugation, each serum sample was divided in two 
aliquots. One aliquot from each sample was sent in ambient temperature to 
the laboratory and analysed upon arrival, and the other one stored at -20 ºC 
awaiting  transport on dry ice to the laboratory in October 2006. The study 
was based on the samples stored at -20 ºC. The analytical results from the 
aliquots sent at ambient temperature were used by the attending 
veterinarians for clinical management of the diabetic dogs. The 
concentrations of C-peptide were significantly lower in serum samples 
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stored at -20 ºC than in those that had been sent to the laboratory at an 
ambient temperature and analysed upon arrival. The mean difference was 
0·05 nmol/l, with a range from 0 to 0·16 mmol/l.  C-peptide in human 
samples is known to be sensitive to storage at -20 ºC if stored without the 
protease inhibitor aprotinin (Myrick et al.,  1989). Hence, the C-peptide 
results in paper II should not serve as a reference range for C-peptide 
measured in fresh serum. Table 2 shows a small-scale stability study for 
samples stored in room temperature for 48 hours with and without 
aprotinin. From the experience of this study, it can be concluded that C-
peptide stability must be taken in consideration, when designing of similar 
studies. One opportunity may be to use samples sent at ambient temperature 
with aprotinin added to the sample. The sera for the C-peptide analysis in 
paper IV were stored at -80 ºC, after arrival to the laboratory.  
Table 2. Concentrations of C-peptide (nmol/L) in three dog serum samples after storage with and 
without the protease inhibitor aprotinin at room temperature for 48 h  
  0h  24h  48h 
sample 1      
stored without aprotinin  0.13  0.13  0.10 
stored with aprotinin  0.13  0.13  0.13 
      
sample 2      
stored without aprotinin  0.17  0.13  0.20 
stored with aprotinin  0.17  0.17  0.17 
      
sample 3      
stored without aprotinin  0.27  0.27  0.20 
stored with aprotinin  0.33  0.30  0.27 
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5  Results and discussion 
A detailed discussion of each specific study is given in the respective papers. 
In the general discussion below, the principal features of the investigations 
are summarised and a new classification system for diabetes mellitus in dogs 
is proposed. 
5.1  Epidemiology 
5.1.1  Frequency of diabetes mellitus in Swedish insured dogs 
There are different ways of expressing disease frequency, but the two of the 
most common are prevalence and incidence rates. Prevalence relates to the 
number of affected animals existing at a specific point in time. The 
incidence rate refers to the number of new cases per animal-time unit at 
risk. Prevalence is dependent on the duration of disease, and on the length 
of time for which an animal survives with the disease, and is therefore 
generally not appropriate for use in research on risk factors for disease.  
The study population in study I comprised more than 180,000 dogs (51% 
females), aged 5-12 years, of 294 breeds, contributing a total of 670,000 years 
at risk. Claims for diabetes mellitus had been submitted for 860 of the dogs. 
Incidence rates for all dogs and by gender are shown in Table 3. 
Table 3. Incidence rates of diabetes mellitus in a population of insured dogs  
n, number of new cases 
 
Animals  N  Years at risk  Incidence rate, cases per 10,000 years at risk  
(95% confidence interval) 
All  860  652,898  13 (12-14) 
Male  242  318,406  8 (7-9) 
Female  618  334,491  19 (17-20)   40
The incidence varied by breed, with the Australian terrier, samoyed, 
Swedish Lapphund, Swedish elkhound and border collie having the highest 
rates (45-183 cases/10,000 years at risk) and the papillon and boxer having 
the lowest (0 cases/10,000 years at risk). For all breeds with more than 40 
cases, a cumulative percentage of affected dogs was calculated and these 
figures are shown in Table 4 at 8, 10 and 12 years.  
The risk of misclassification was deemed small in this study. Most 
veterinarians can both readily recognise the symptoms and diagnose the 
dogs. Furthermore, diabetes mellitus lead to death if left untreated. Hence, 
most insured diabetic dogs are assumed to eventually be diagnosed by a 
clinician.  
The finding that certain breeds are at high or low risk for diabetes 
mellitus confirms the results of previous studies (Davison et al., 2005; Guptill 
et al.,  2003; Hess et al.,  2000a) with the exception of a number of 
Scandinavian breeds, such as the Swedish elkhound, Swedish Lapphund, the 
drever and the Hamilton hound, which we hound to be at high risk in our 
study. This is probably because these breeds are uncommon outside 
Scandinavia. 
It is possible to extrapolate most of the results from paper I to the general 
Swedish dog population in the age group studied. The results are generally 
not valid for extrapolation to non-Scandinavian countries mainly due to the 
different breed distribution and elective neuter routines. 
Table 4. Cumulative percentages of dogs that had developed diabetes at 8, 10 and 12 years of age. Data 
based on 860 cases of diabetes in a population of 180,000 insured dogs. 
5.1.2  Age at onset 
The mean age at the first insurance claim for diabetes mellitus was found to 
be 8.6 years in study I. For gestational diabetes (study III), the median age at 
diagnosis was 5.9 years. In study IV, the mean age at diagnosis of non-
 Percentage  (95% CI) 
  8 years   10 years   12 years  
All  0.3 (0.2-0.3)  0.7 (0.7-0.8)  1.2 (1.1-1.2) 
Females  0.4 (0.3-0.4)  1.0 (0.9-1.1)  1.6 (1.5-1.7) 
Males  0.1 (0.1-0.2)  0.4 (0.3-0.5)  0.6 (0.5-0.7) 
Border collie  0.4 (0.1-0.6)  2.2 (1.5-2.8)  3.4 (2.3-4.4) 
Sw. Elkhound  1.3 (0.8-1.8)  2.5 (1.7-3.3)  3.6 (2.3-4.9) 
Samoyed  1.9 (0.9-2.8)  5.3 (3.4-7.1)  9.0 (5.9-12.0) 
Labrador   0.2 (0.1-0.3)  0.6 (0.4-0.9)  1.3 (0.9-1.7) 
Drever  0.7 (0.4-1.0)  2.4 (1.7-3.1)  3.0 (2.2-3.9) 
CI, confidence interval   41 
pregnant dogs was 8.0 years. In study I, the mean age at the first insurance 
claim varied by breed. The Swedish elkhound had the youngest age at first 
claim (7.8 years) and the cairn terrier and west highland white terrier had 
the oldest (9.3  years). There is a time lag from the first symptoms until 
diagnosis, the mean of which was estimated in study IV to be 21 days. 
However, some owners do not consult a veterinarian until months later in 
the disease process.  
5.1.3  Gender 
Of the 860 diabetes cases in study I, 618 (72%) were of female gender and 
242 dogs were males (28%). The proportion of female cases varied 
significantly by breed, with Swedish elkhounds, Norwegian elkhounds and 
border collies having the highest proportion (98-100%) and the rottweiler 
and Labrador retriever the lowest (33-51%, but with CIs overlapping 0.5). 
Within the scdmp, however, a small breed, the Polish Lowland Sheepdog, 
seemed to have a male predilection. Of 14 confirmed cases, only two were 
females (unpublished data). The finding of a high proportion of female 
elkhounds was confirmed in study IV, which is further discussed in section 
4.8. 
In populations where juvenile spay of dogs is common, the increased risk 
of diabetes in females seems to have been eradicated (Davison et al., 2005). 
Hence, the increased risk of diabetes in females is probably explained mainly 
by diœstrous diabetes and also the more rare form gestational diabetes. If we 
simply assume that the risk of other types of diabetes is equal between 
genders, the total number of male cases subtracted from the total number of 
females would equal the sum of diœstrous diabetes. That calculation crudely 
estimates the proportion of diœstrus/gestational diabetes mellitus in the 
population studied in study 1, to 44% (376/860), and the proportion among 
female dogs 60% (376⁄618). See Figure 5.    42
Figure 5. Estimation of diabetic cases related to female gender (probable dioestrus diabetes) 
versus other causes unrelated to gender. Based on 860 cases of diabetes mellitus in the Agria 
database 1995-2004.  
5.1.4  Survival after diagnosis 
In study I, the median survival time (n=686, deaths=413) after the first 
diabetes mellitus claim was 57 days among all dogs and 2.0 years among dogs 
surviving the first day after diagnosis. The risk of dying is clearly highest 
early after diagnosis, probably on account of unwillingness to treat the dog, 
but also because of complications such as ketoacidosis. Breed was shown to 
influence the survival after diagnosis. The hunting dog breeds, in particular, 
have a high mortality at day of diagnosis. In study IV, the median survival 
time was much longer, but it should be noted that the recruitment of dogs 
for that study was biased towards dogs with longer survival and less 
euthanasia.  
5.1.5  Other diseases as risk factors for diabetes mellitus 
In study I, the hazard ratio for development of diabetes in dogs with 
hyperadrenocorticism was 9.3 (95% ci, 5.4-15.9) compared to dogs without 
hyperadrenocorticism. Pancreatitis, pancreatic insufficiency, adrenocortical 
insufficiency and hypothyroidism were evaluated as risk factors for diabetes, 
but were not found to contribute to the models, neither increasing nor 
decreasing the risk of diabetes. Those diseases (except for hypothyroidism) 
may have been under-diagnosed in the population, and should not be 
excluded as potential risk factors for diabetes mellitus. Further studies are 
therefore required. 
female male
0
200
400
600
800
other causes
probable dioestrus diabetes
N
o
 
o
f
 
c
a
s
e
s
other causes 
probable dioestrous diabetes 
N
o
.
 
o
f
 
c
a
s
e
s
   43 
5.2  Glucagon stimulation test 
In paper II, the glucagon stimulation test was evaluated for dogs and found 
effective in increasing blood glucose, insulin and C-peptide concentrations 
in healthy dogs. In diabetic dogs, most dogs had low concentrations of C-
peptide and insulin and high concentrations of glucose. A few newly 
diagnosed female dogs had normal to high C-peptide concentrations, 
indicative of residual beta cell mass. The test is of potential value for 
classifying the type of diabetes in newly diagnosed dogs (see section 6.10). 
5.3  Diabetes mellitus in elkhounds 
In the studies summarised in this thesis several important conclusions were 
drawn regarding diabetes in Swedish and Norwegian elkhounds: 
 
  Diabetes predominantly affects female dogs (I, IV) 
  Although gestational diabetes is uncommonly diagnosed in dogs in 
general, elkhounds seem to be predisposed to the syndrome (III) 
  In non-pregnant elkhounds, the first symptoms of diabetes occur 
shortly after œstrus (IV) 
  Dogs may recover from diabetes after pregnancy or at the end of 
diœstrus (III, IV) 
  The probability of remission is associated with the glucose 
concentrations at diagnosis and the length of the interval from the first 
symptoms to ovariohysterectomy (IV). Hence, in dogs with dioestrus 
diabetes, treatment directed against the source of the insulin resistance 
s h o u l d  b e  i n i t i a t e d  a s  s o o n  a s  possible after diagnosis to avoid 
glucotoxic effects on beta cells 
On the basis of the findings in this doctoral research, it is concluded that 
elkhounds must be genetically predisposed to diœstrous and gestational 
diabetes. The elkhounds could be a helpful link in explaining the genetic 
background to human gestational diabetes in the future. Other breeds with a 
high female incidence, such as the border collie and the beagle, may have 
similar clinical features. This may be important in experimental animal 
research, as beagle is usually the breed studied. Many studies concerning the 
impact of progestin upon glucose metabolism are carried out in beagles, and 
it would be interesting to repeat them in breeds not commonly affected by 
diœstrous diabetes.   44
5.4  Review of existing classification systems 
A major requirement for epidemiological, genetic and clinical research on 
diabetes mellitus and for its clinical management is an appropriate system of 
classification that provides a framework within which its various forms and 
stages can be to identified and differentiated (American diabetes 
organisation, 2003).  
Several attempts to classify canine diabetes have been made over the 
years. It has been proposed that canine diabetes is comparable to lada 
(Catchpole et al., 2005; Rand et al., 2004). This comparison was motivated 
by the fact that canine diabetes commonly affects middle-aged to older dogs 
and that newly diagnosed animals have higher stimulated C-peptide levels 
than those that have had the diagnosis for more than a year (Montgomery et 
al., 1996). I would like to argue against this comparison, as patients with 
lada do not by definition (Fourlanos et al., 2005) require insulin for the first 
six months, in contrast to most diabetic dogs. Moreover, the decline in the 
C-peptide response to glucagon during the years after diagnosis is seen in 
many forms of diabetes, including type 1 (Palmer, 2009). 
The iddm⁄niddm classification system was used in humans until 1999 and 
is still often used for dogs. It is based on the question whether a diabetic 
patient needs insulin (iddm) or not (niddm). Since most diabetic dogs are 
treated with insulin from the onset of the disease, they would all be classified 
as  iddm. Such a classification system does not help the clinician at all 
regarding the prognosis and treatment options. Thus, this is not a good 
classification system for use in dogs.  
Catchpole et al. (2005) suggested a system whereby dogs are divided into 
two groups depending on the cause of the disease, namely insulin deficiency 
or insulin resistant diabetes. The system is attractive in many ways, as it 
addresses the aetiology of the disease. However, some problems remain. The 
first is that the majority of the cases are still idiopathic, and the system does 
not providing a good classification for such cases. Another problem is the 
difficulty in communication with human diabetologists, as they tend to 
interpret the two categories directly as type 1 and type 2 diabetes. 
Furthermore, since dogs seem to pass from an insulin resistant state into 
insulin deficiency through glucotoxicity within weeks after diagnosis, it may 
be confusing to place them in either class. 
For the above reasons, a modified system for classifying diabetes mellitus 
in dogs constructed in a fashion similar to that in human medicine (see 
Table 1) is proposed, as discussed below.    45 
5.5  A new classification system for canine diabetes mellitus 
A new system for classification of diabetes mellitus in dogs is proposed and 
presented in Table 5. The system is based on current knowledge and is an 
attempt to categorise diabetes mellitus in dogs according to its cause. When 
more is learned about the pathogenesis of diabetes in dogs, this system will 
need to be reviewed and revised accordingly.  
Table 5. Aetiological classification of diabetes mellitus in dogs 
Classification in dogs  Corresponding class in human system (Table 1) 
Juvenile diabetes mellitus 
A.  Beta cell hypoplasia 
B.  Combined beta cell deficiency and 
pancreatic acinar atrophy  
 
None 
None 
Progesterone-related 
A.  Gestational  
B.  Diœstrous  
 
Class IV 
Secondary to pancreatitis  Class III:C:1 
Endocrine tumours 
A.  Hyperadrenocorticism 
B.  Acromegaly 
C. Glucagonoma 
 
Class III:D:2 
Class III:D:1 
Class III:D:3 
Iatrogenic 
A.  Glucocorticoids 
B.   Progestin 
C.  Secondary to insulinoma treatment 
 
Class III:E:4 
Class III:E:11 
Class III:C:2/Class III:E:11 
Immune-mediated diabetes mellitus
6 Class  IA 
Idiopathic diabetes mellitus   None  
5.5.1  Juvenile diabetes mellitus 
Beta cell hypoplasia 
This form of diabetes is diagnosed  before the age of six months. Biopsies of 
the pancreas reveal a small number of islets, without signs of insulitis or 
exocrine pancreatic inflammation (Minkus et al., 1997; Atkins et al., 1988). 
Dogs are insulinopenic at diagnosis. This form of diabetes is mainly seen in 
keeshonds but a few cases have also been reported in golden retrievers, 
poodles and Labrador retrievers (Minkus et al., 1997; Atkins et al., 1988; 
Kramer et al., 1980).  
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Combined beta cell deficiency and pancreatic acinar atrophy  
This form of diabetes is diagnosed before the age of six months. Aside from 
symptoms of diabetes, the dog may show diarrhoea and weight loss. Blood 
analysis reveals concurrent exocrine pancreatic insufficiency and 
insulinopenic diabetes mellitus. Reported histopathological findings include 
lesions in both the endocrine and exocrine pancreas, with acinar cell 
apoptosis, zymogen granule loss, cytoplasmic clearing or vacuolar changes, 
lobular atrophy and islet loss. In greyhounds, a lymphocytic or 
lymphoplasmacytic pancreatitis is also reported (Brenner et al., 2009). This 
form of diabetes mellitus is seen in greyhounds and German shepherds 
(Brenner et al., 2009; Neiger et al., 1996; Atkins et al., 1988; Ling et al., 
1977). Many of the reported cases are euthanised shortly after diagnosis.  
5.5.2  Progesterone-related 
A.  Gestational 
Gestational diabetes, which is described in detail in paper III, is defined as 
diabetes with onset during pregnancy. It is considered uncommon in dogs 
(Johnson,  2008) and there are only two case reports in the literature 
(Norman et al., 2006). Dogs may be treated with abortion, caesarean section, 
or insulin. The diabetes may resolve after the end of pregnancy. This form 
of diabetes has been reported mainly in Nordic Spitz breeds, but also in a 
German shepherd and a Labrador retriever (Norman et al., 2006; paper III). 
B.  Diœstrous 
Here the onset is during the luteal phase of the œstrous cycle in an intact 
female dog. Insulin/C-peptide may be high initially, and the diabetes can 
resolve after ovariohysterectomy (Eigenmann et al., 1983; paper IV). Within 
the  scdmp, diœstrous diabetes mellitus has been seen in several breeds, 
including the elkhounds, border collie, Australian kelpie, Irish setter and 
beagle. Pancreatic biopsies reveal vacuolisation of islets and a decreased 
number of islets (Eigenmann et al.,  1983). In section 5.1.3, a rough 
estimation of the proportion of diœstrous diabetes in the Swedish dog 
population is 60% of all female diabetes cases.  
5.5.3  Secondary to pancreatitis 
In this form of diabetes, a diagnosis of pancreatitis precedes the onset of 
diabetes. There have been several studies on dogs suffering from diabetes 
concurrently with acute or chronic pancreatitis (Hess et al., 2000b; Alejandro 
et al., 1988) but none in which the causal association has been established. In   47 
cases of combined pancreatitis and diabetes, exocrine pancreatic 
insufficiency may also develop (Watson, 2003) .  D o g s  w i t h  b o t h  c h r o n i c  
pancreatitis and diabetes may be challenging to treat, because of the lack of 
effective treatments for the former condition. Chronic pancreatitis in 
combination with diabetes has been reported to occur in English cocker 
spaniels (Watson et al., 2006). A relation between previous pancreatitis and 
diabetes was not confirmed in the present study I, but since the chronic 
pancreatitis may be strongly under-diagnosed the power of the analysis was 
low. 
5.5.4  Endocrine tumours 
A.  Hyperadrenocorticism/Cushing’s disease 
In this form of diabetes, a diagnosis of hyperadrenocorticism precedes the 
onset of diabetes. High concentrations of insulin/C-peptide may be found at 
early stages, and if the primary disease is correctly treated, the diabetes may 
resolve (Campbell & Latimer, 1984; Peterson et al., 1984). If no beta cells 
remain in a dog with hyperadrenocorticism, the prognosis is worse, because 
of the clinical challenge of treating this double endocrine disorder (Peterson 
et al.,  1981). The relation between previous hyperadrenocorticism and 
diabetes was confirmed in study I. 
B.  Acromegaly 
Pituitary-dependent acromegaly is uncommon in dogs. There are two case 
reports of dogs with pituitary tumours and insulin resistance, which 
proceeded to overt diabetes in one dog (Fracassi et al., 2007; van Keulen et 
al., 1996). Both dogs were euthanised.  
C.  Glucagonoma 
Dogs with pancreatic glucagon-producing tumours may develop diabetes 
and superficial necrolytic dermatitis. It has been reported that dogs develop 
diabetes in the later stages of the illness, months after the skin disease is first 
observed (Gross et al., 1990). In reported cases, dogs have been euthanised 
because of post-surgical complications. 
5.5.5  Iatrogenic 
A.  Glucocorticoid treatment 
The iatrogenic form of diabetes due to hypercortisolism has been reported 
to occur in dogs treated with oral and parenteral glucocorticoid therapy.   48
The diabetes may resolve after the medication has been discontinued (Jeffers 
et al., 1991; Campbell & Latimer, 1984). 
B.  Progestin 
This form of diabetes occurs in female dogs after administration of 
progestins, e.g. medroxyprogesterone (Bhatti et al., 2006; Selman et al., 1997; 
Eigenmann et al., 1983; Eigenmann & Rijnberk, 1981). The diabetes may 
occur transiently if progestin administration is discontinued or if the dog is 
treated with a progesterone antagonist such as aglépristone (Bhatti et al., 
2006). Within the scdmp, a case of transient diabetes in a male dog was 
noted. This dog, a 6-year-old German pointer was treated for prostatic 
hyperplasia with medroxyprogesterone (Promon®)(unpublished data). 
C.  Secondary to insulinoma treatment 
Insulinoma, a rare beta cell tumour, may be treated with surgery or 
medically. Medical treatment may consist of dietary changes, administration 
of glucocorticoids, and in some cases streptozocin. Diabetes is a well known 
complication of treatment with streptozocin and insulinoma surgery (Bell et 
al., 2005; Moore et al., 2002; Tobin et al., 1999). The prognosis in this type 
of diabetes depends on whether the insulin-secreting tumour has 
metastasised or not.  
5.5.6  Immune-mediated diabetes 
For allocation to the class immune-mediated diabetes in dogs, the diagnostic 
criteria and tools need to be r e f i n e d .  H o e n i g  a n d  D a w e  ( 1992) found 
nonspecific anti-islet reactivity in nine out of 23 dogs of various breeds 
newly diagnosed with diabetes. Davison et al (2008) found increased gad65 
and IA-2 antibody reactivity in five out of 30 newly diagnosed dogs 
compared to controls. The increases were much smaller than what is seen in 
human type 1 diabetes. The auto-antibody positive dogs were mainly 
crossbred. It is not clear whether these antibodies are part of the cause of 
diabetes in these cases or a consequence of beta cell destruction due to other 
causes. More studies on this subject are needed. Preliminary results from our 
own work did not confirm the presence of autoantibodies to gad65 in three 
o f  t h e  s e r a  r e p o r t e d  p o s i t i v e  f r o m  the Davison study. Further, we have 
screened 120 diabetic and 120 healthy control sera from Swedish dogs for 
autoantibodies with immunofluorescence techniques including dog 
pancreata and a certified islet cell antibody assay (ica) using human 
pancreata. All samples tested negative for pancreatic autoantibodies (personal 
communication, Kerstin Ahlgren, Dept. of Medical Sciences, Uppsala). If 
autoimmunity occurs at all in the dog, it might be T-cell mediated, and   49 
there could be a need for research on reactive T cells, similar to that 
performed in Japanese type 1b human patients (Shimada et al., 2003). 
5.5.7  Idiopathic diabetes 
Idiopathic diabetes is the most frequently reported form of diabetes in the 
dog. This class will hopefully be reduced as more information is acquired 
about canine diabetes. It is important that clinicians try to exclude the other 
types of diabetes before subtyping it as idiopathic. 
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6  Conclusions 
  Canine diabetes mellitus comprises a group of heterogeneous disorders 
resulting in a hyperglycaemic state which gives rise to similar symptoms 
among affected dogs. 
  The distribution of the different subtypes of canine diabetes mellitus 
differs between breeds, indicating different genetic predispositions for the 
different subtypes. 
  Survival after diagnosis varies by breed, probably depending on a 
combination of the owner’s willingness to treat and potentially also the 
subtype of diabetes mellitus. 
  The glucagon stimulation test is effective and safe for assessing beta cell 
function in dogs. 
  Elkhounds are predisposed to gestational and diœstrous diabetes and may 
serve as a useful animal model for human gestational diabetes in ongoing 
genetic studies of the disease. 
  The probability of remission from diœstrous diabetes mellitus is 
associated with the time from onset of symptoms to surgery, and with 
the glucose concentrations at diagnosis. 
  Progesterone concentrations are similar in dogs with diœstrous diabetes 
and healthy dogs. 
  Dogs with gestational diabetes can be difficult to control with insulin. In 
some cases, usually when the pregnancy is quickly terminated, dogs 
recover from diabetes. 
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7  Future research 
New insights have been gained regarding the characteristics of canine 
diabetes mellitus. However, several areas have been indentified in which 
studies are ongoing or further research is needed: 
 
  A genome-wide association study with 60 cases and 100 controls is under 
way for mapping genetic variants associated with diabetes in elkhounds. 
  Epidemiological studies addressing effects of environmental risk factors 
such as exercise and nutrition upon the risk of developing various types 
of canine diabetes have been initiated. 
  Further investigations of breed-specific characteristics of diabetes mellitus 
are required. 
  Studies addressing the hypothesis that abnormalities in the gh/igf-1 axis 
is a component of the development of diabetes in elkhounds. 
  The role of autoimmunity in the development of canine diabetes needs 
to be analysed further. 
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8  Populärvetenskaplig sammanfattning 
8.1.1  Diabetes mellitus hos hund 
Diabetes mellitus (sockersjuka) är ett stort folkhälsoproblem som även 
drabbar hundar. Diabetes mellitus är inte en enskild sjukdom utan en 
gemensam benämning för flera olika sjukdomar som alla karaktäriseras av 
höga blodsockernivåer. Det höga blodsockret orsakas antingen av för låg 
produktion eller otillräcklig effekt av det blodsockersänkande hormonet 
insulin. För såväl hund som människa är ökad törst, ökad urinvolym, ökad 
aptit och avmagring klassiska symptom på diabetes mellitus. De flesta hundar 
som drabbas är äldre än fem år. Fler tikar än hanhundar insjuknar och vissa 
raser har visat sig vara mer drabbade än andra. 
Diagnosen ställs genom att mäta sockerhalten (glukos) i blod och urin. 
Hundar med diabetes behöver oftast livslång behandling med 
insulininjektioner. Många hundar avlivas direkt när de fått diagnosen. En tik 
som fått diabetes bör kastreras eftersom det är välkänt att tikens långa 
efterlöpsperioder påverkar blodsockernivåerna negativt.  
Hundar är idealiska för studier av sjukdomars genetiska bakgrund 
eftersom individerna inom varje hundras är genetiskt mycket lika men olika 
jämfört med individer av andra raser. För att bestämma den genetiska 
bakgrunden till diabetes hos hund behövs mer kunskap om huruvida det 
finns olika former av hundens diabetes. Sådan kunskap kan också vara till 
stor nytta i det kliniska arbetet med diabetessjuka hundar då det troligtvis är 
olika prognos och behandling som krävs vid de olika formerna av diabetes 
mellitus. 
8.1.2  Typer av diabetes mellitus hos människa 
Hos människa finns ett stort antal olika typer av diabetes mellitus beskrivna. 
De tre vanligaste är typ 1-diabetes, typ 2-diabetes och graviditetsdiabetes. 
Typ  1-diabetes drabbar oftast barn och ungdomar och beror på en   56
autoimmun nedbrytning av de insulinproducerande cellerna i 
bukspottkörteln.  Patienter med typ 1–diabetes behöver insulininjektioner 
dagligen hela livet. Typ-2 diabetes drabbar oftast vuxna och beror på en 
kombination av nedsatt känslighet för insulin i vävnaderna och en nedsatt 
förmåga att tillverka tillräckliga mängder insulin. Den minskade känsligheten 
kan bland annat relateras till övervikt och brist på motion. Patienter med 
denna typ av diabetes kan behandlas med särskild kost, motion, 
blodsockersänkande tabletter men kan ibland även behöva 
insulininjektioner. Graviditetsdiabetes är en ganska vanlig komplikation vid 
graviditet. Under en normal graviditet måste kroppen tillverka mer insulin 
eftersom insulinkänsligheten minskar. Om inte kroppen förmår tillverka 
tillräckligt mycket insulin utvecklas diabetes.  
8.1.3  Avhandlingsarbetet 
Syftet med avhandlingsarbetet var att öka kunskapen om diabetes mellitus 
hos hund och då framförallt definiera olika former av syndromet. För att 
uppnå dessa mål utfördes fyra studier. 
I den första studien användes Agria djurförsäkringars databas för att 
studera förekomsten av diagnosen diabetes mellitus under åren 1995-2004. 
Databasen innehöll mer än 180.000 hundar varav 860 fått diagnosen 
diabetes. I studien konstaterades att förekomsten diabetes mellitus varierade 
kraftigt mellan olika raser. Australisk terrier, samojed, svensk lapphund och 
jämthund var de raser som löpte högst risk att utveckla diabetes medan 
papillon och boxer hade lägst risk. Risken för en försäkrad tolvårig svensk 
hanhund att ha insjuknat i diabetes uppskattades till 0,6%, och för en 
försäkrad tolvårig svensk tik 1,6%. I tabell 6 visas skattningar för några av 
högriskraserna. Medelåldern för att insjukna i diabetes var 8,6 år. Många 
hundar avlivades vid diagnos vilket gjorde att medelöverlevnaden var kort, 
bara 56 dagar. För hundar som levde mer än en dag efter diagnos, det vill 
säga hundar som inte avlivades direkt eller var akut döende, var 
medelöverlevnaden två år efter diagnos.  
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Table 2. Risken att ha insjuknat i diabetes mellitus vid 8, 10 och 12 års ålder hos några av riskraserna 
för diabetes. Tabellen baseras på försäkringsdata från Agria djurförsäkringar.  
 
Ett anmärkningsvärt fynd i denna studie var att i stort sett bara tikar 
drabbades i vissa raser (jämthund, gråhund och border collie). i I övriga raser 
var ungefär 60% av de drabbade hundarna tikar.  
I följande studie testades insulinproduktionen hos både friska hundar och 
diabetessjuka hundar med ett test; ”glukagonstimuleringstest”. Detta test 
används ofta på människor för att bedöma förmågan till insulinproduktion. 
Blodprover analyserades från hundarna före samt tio och tjugo minuter efter 
en injektion av det blodsockerförhöjande läkemedlet glukagon. Vi såg att 
hundar med diabetes mellitus generellt hade lägre insulinproduktion jämfört 
med friska hundar. Det fanns några diabetessjuka hundar som hade en 
normal insulinproduktion, vilket troligtvis innebar att de hade en nedsatt 
känslighet för insulin.  
I den tredje studien sammanställdes information om hundar som drabbats 
av diabetes mellitus under dräktighet. Denna form av diabetes mellitus är 
ovanlig och de vetenskapliga rapporterna i litteraturen är få. Genom den här 
studien finns nu en samlad information om när under dräktigheten hundar 
drabbas, vilka blodanalysvärden hundarna har samt vilken prognosen är. 
Studien visade att det är svårt att medicinskt behandla dräktiga hundar med 
diabetes mellitus och att sjukdomen ofta blir permanent hos dräktiga hundar 
som insulinbehandlats. Många tikar tillfrisknar dock helt om dräktigheten 
avbryts via abort eller kejsarsnitt. Tiken bör sedan kastreras för att förhindra 
återfall i samband med nästa löp. 
I den fjärde studien undersökte vi två raser där nästan enbart tikar drabbas 
av diabetes mellitus. Information och blodprover insamlades från 63 
diabetessjuka jämt- och gråhundar med och från 26 friska hundar av dessa 
raser. I studien såg vi att samtliga fall av diabetes mellitus drabbade 
okastrerade tikar och att de hade fått sina första symptom kort efter avslutat 
löp. Efter varje löp är koncentrationen av det dräktighetsbevarande 
hormonet progesteron hög och även icke-dräktiga hundar genomgår en 
period av så kallad skendräktighet. Det är under denna period som hundar i 
  8 år 10 år  12 år 
Samtliga raser  0.3 %  0.7 %  1.2 % 
Tikar  0.4 %  1.0 %  1.6 % 
Hanhundar  0.1 %  0.4 %  0.6 % 
Border collie  0.4 %  2.2 %  3.4 % 
Jämthund  1.3 %  2.5 %  3.6 % 
Samojed  1.9 %  5.3 %  9.0 % 
Drever  0.7 %  2.4 %  3.0 %   58
dessa raser drabbas av diabetes. Vi mätte nivåerna av progesteron och 
jämförde med de friska hundarna som också var provtagna efter avslutad 
löpperiod. Det gick inte att påvisa någon skillnad mellan friska och sjuka 
hundar avseende progesteronvärden. Fyrtiosex procent av tikarna 
tillfrisknade helt från sin sjukdom efter kastration. Vi studerade riskfaktorer 
för att inte bli frisk efter kastration och såg att ett högt blodsockervärde vid 
diagnos och en lång väntetid mellan diagnos och kastration ökade risken för 
permanent diabetes.  
Avhandlingen avslutas med att författaren föreslår ett nytt system att 
klassificera diabetes mellitus hos hund. Klassificeringen är baserad på de nya 
kunskaperna från studierna i avhandlingen samt på kunskaper sammanställda 
från befintlig litteratur. Följande klassindelning föreslås: 
Tabell 7. Klassindelning av diabetes mellitus hos hund 
 Juvenil diabetes mellitus 
A. Betacellhypoplasi 
B.  Kombinerad betacellsbrist och bukspottkörtelatrofi  
 Progesteronrelaterad 
A. Dräktighetsdiabetes  
B.  Diöstrusdiabetes  
Sekundärt till bukspottkörtelsjukdom 
Endokrina tumörer 
A. Cushings sjukdom 
B.  Akromegali 
C. Glukagonom 
Iatrogen (Läkemedelsorsakad) 
A. Glukokortikoider 
B.  Progesteronpreparat 
C. Sekundärt till insulinom-behandling  
Immunmedierad diabetes mellitus
7 
Idiopatisk diabetes mellitus 
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